Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific clinical manifestations in the early stages, the diagnosis o...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2025-05-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2025.102.18 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850135364072636416 |
|---|---|
| author | Jie YANG Fanming KONG |
| author_facet | Jie YANG Fanming KONG |
| author_sort | Jie YANG |
| collection | DOAJ |
| description | Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific clinical manifestations in the early stages, the diagnosis of MPM presents a significant challenge, leading to most patients being diagnosed at an advanced stage, which limits the effectiveness of surgical treatment. Consequently, systemic therapies are commonly required. Although Pemetrexed in combination with Platinum-based chemotherapy remains the first-line standard treatment for unresectable MPM, its therapeutic efficacy is limited, and more effective treatment strategies are urgently needed. In recent years, immune checkpoint inhibitors have made significant progress in the treatment of MPM, markedly improving patient survival outcomes. With the increasing depth of molecular biological research on MPM, targeted therapies offer promising personalized treatment options. Additionally, the therapeutic potential of novel strategies such as cell therapy and oncolytic virus therapy is beginning to emerge. This review summarizes the latest advancements in the medical treatment of MPM and looks forward to future therapeutic directions, aiming to provide insights for clinical practice. |
| format | Article |
| id | doaj-art-dfade62e264448bd8ad5c24b54e9bcf7 |
| institution | OA Journals |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2025-05-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-dfade62e264448bd8ad5c24b54e9bcf72025-08-20T02:31:27ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872025-05-0128539139910.3779/j.issn.1009-3419.2025.102.18Recent Advances in Medical Treatment of Malignant Pleural MesotheliomaJie YANG0Fanming KONG1Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
Tianjin 300381, ChinaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,
Tianjin 300381, ChinaMalignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific clinical manifestations in the early stages, the diagnosis of MPM presents a significant challenge, leading to most patients being diagnosed at an advanced stage, which limits the effectiveness of surgical treatment. Consequently, systemic therapies are commonly required. Although Pemetrexed in combination with Platinum-based chemotherapy remains the first-line standard treatment for unresectable MPM, its therapeutic efficacy is limited, and more effective treatment strategies are urgently needed. In recent years, immune checkpoint inhibitors have made significant progress in the treatment of MPM, markedly improving patient survival outcomes. With the increasing depth of molecular biological research on MPM, targeted therapies offer promising personalized treatment options. Additionally, the therapeutic potential of novel strategies such as cell therapy and oncolytic virus therapy is beginning to emerge. This review summarizes the latest advancements in the medical treatment of MPM and looks forward to future therapeutic directions, aiming to provide insights for clinical practice.http://dx.doi.org/10.3779/j.issn.1009-3419.2025.102.18malignant pleural mesotheliomamolecular targeted therapyimmunotherapychemotherapycombination therapy |
| spellingShingle | Jie YANG Fanming KONG Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma Chinese Journal of Lung Cancer malignant pleural mesothelioma molecular targeted therapy immunotherapy chemotherapy combination therapy |
| title | Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma |
| title_full | Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma |
| title_fullStr | Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma |
| title_full_unstemmed | Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma |
| title_short | Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma |
| title_sort | recent advances in medical treatment of malignant pleural mesothelioma |
| topic | malignant pleural mesothelioma molecular targeted therapy immunotherapy chemotherapy combination therapy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2025.102.18 |
| work_keys_str_mv | AT jieyang recentadvancesinmedicaltreatmentofmalignantpleuralmesothelioma AT fanmingkong recentadvancesinmedicaltreatmentofmalignantpleuralmesothelioma |